Stock Story -
Personal care company Nu Skin (NYSE:NUS) will be reporting earnings tomorrow after the bell. Here’s what to expect.
Nu Skin beat analysts’ revenue expectations by 1.7% last quarter, reporting revenues of $439.1 million, down 12.2% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ EBITDA estimates but underwhelming earnings guidance for the full year.
Is Nu Skin a buy or sell going into earnings? Find out by reading the original article on StockStory, it’s free.
This quarter, analysts are expecting Nu Skin’s revenue to decline 11.6% year on year to $441 million, a further deceleration from the 7.3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.20 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Nu Skin has missed Wall Street’s revenue estimates five times over the last two years.
Looking at Nu Skin’s peers in the personal care segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Herbalife’s revenues decreased 3.2% year on year, missing analysts’ expectations by 1%, and Medifast (NYSE:MED) reported a revenue decline of 40.6%, topping estimates by 1.5%. Herbalife (NYSE:HLF) traded up 10.2% following the results while Medifast was also up 8.6%.
Read the full analysis of Herbalife’s and Medifast’s results on StockStory.
Investors in the personal care segment have had steady hands going into earnings, with share prices up 1.2% on average over the last month. Nu Skin’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $9.58 (compared to the current share price of $6.43).